SMMT
Summit Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$15.62
−3.57%Next report
Analyst consensus
- Next report date
- Nov 2, 2026
- EPS estimate
- -$0.28
- Revenue estimate
- $71.4K
Latest reported
- Last report date
- Jul 23, 2026
- EPS actual
- -$0.28
- EPS estimate
- -$0.27
- Revenue actual
- —
- Revenue estimate
- $114.0K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 5
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- -15.5%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Hold
- Price target
- $23
- PT range
- $12 – $43
- Analysts
- 6
2 Buy4 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Jul 23, 2026 | -$0.27 | -$0.28 | Miss -2.04% | — |
| Jun 1, 2026 | -$0.28 | -$0.24 | Beat 13.12% | — |
| Oct 20, 2025 | -$0.18 | -$0.31 | Miss -76.37% | — |
| May 1, 2025 | -$0.09 | -$0.09 | Beat 3.25% | — |
| Oct 30, 2024 | -$0.07 | -$0.08 | Miss -14.29% | — |
| May 1, 2024 | -$0.06 | -$0.06 | In line | — |
| Feb 20, 2024 | — | -$0.04 | — | — |
| May 11, 2023 | — | -$0.06 | — | — |
| Mar 9, 2023 | -$0.26 | -$0.07 | Beat 73.08% | $705 |
| Nov 9, 2022 | -$0.26 | -$0.14 | Beat 46.15% | $220.0K |
| Aug 11, 2022 | -$0.27 | -$0.17 | Beat 37.04% | $235.0K |
| Mar 17, 2022 | -$0.27 | -$0.28 | Miss -3.70% | $251.0K |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 2, 2026